10-QPeriod: Q1 FY2008

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2008

Filed May 8, 2008For Securities:DXCM

Summary

This 10-Q filing for DexCom, Inc. (DXCM) for the quarter ended March 31, 2008, highlights the company's continued investment in research and development and commercialization efforts for its continuous glucose monitoring (CGM) systems, particularly the SEVEN product line. While product revenues saw an increase compared to the prior year, the company reported a net loss for the quarter, consistent with its historical performance as an early-stage medical device company. Significant investments in R&D and selling, general, and administrative expenses are driving these losses, which the company anticipates will continue in the near future as it scales operations and seeks market adoption and third-party reimbursement for its products. Financially, DexCom maintained a healthy cash position, supplemented by its marketable securities and a credit facility, which management believes is sufficient for at least the next twelve months. However, the company's substantial debt from convertible senior notes and ongoing net losses underscore the need for continued fundraising and highlight potential future dilution for existing shareholders. Key challenges remain in achieving widespread market acceptance, securing adequate third-party reimbursement, and navigating ongoing patent litigation with Abbott Diabetes Care.

Key Highlights

  • 1Product revenues increased to $1.8 million for the quarter ended March 31, 2008, up from $1.0 million in the same period of 2007, reflecting growth in the SEVEN product line.
  • 2The company reported a net loss of $13.0 million ($0.44 per share) for the quarter, a widening from the $10.9 million loss ($0.39 per share) in Q1 2007, driven by increased operating expenses.
  • 3Research and development expenses rose to $4.8 million from $4.0 million, and Selling, General & Administrative expenses increased to $6.4 million from $5.4 million, year-over-year.
  • 4Cash, cash equivalents, and short-term marketable securities totaled $50.6 million as of March 31, 2008, providing a cushion for ongoing operations and development.
  • 5The company had $60 million in 4.75% Convertible Senior Notes due in 2027 outstanding, with interest expense increasing due to the notes being outstanding for the full quarter in 2008 compared to a partial period in 2007.
  • 6DexCom is actively engaged in ongoing patent litigation with Abbott Diabetes Care, which poses a significant risk to its product sales and financial condition, regardless of the outcome.
  • 7The company continues to face challenges in obtaining broad reimbursement from third-party payors for its continuous glucose monitoring systems, a critical factor for widespread patient adoption.

Frequently Asked Questions

For the quarter ended March 31, 2008, DexCom reported product revenues of $1.8 million, an increase from the prior year. However, the company incurred a net loss of $13.0 million for the quarter, which is a slight increase from the $10.9 million net loss reported in the same period of 2007. DexCom continues to experience operating losses as it invests heavily in research and development and commercialization efforts. The company has an accumulated deficit of $189.2 million as of March 31, 2008.

As of March 31, 2008, DexCom had $50.6 million in cash, cash equivalents, and short-term marketable securities. This, along with funds available under their loan and security agreement, is believed to be sufficient to meet anticipated cash requirements for at least the next twelve months. The company has historically funded its operations through equity and debt securities offerings.

Key risks include the market acceptance of its continuous glucose monitoring (CGM) products, the challenge of securing adequate reimbursement from third-party payors, significant ongoing patent litigation with Abbott Diabetes Care, the potential dilution from convertible notes, and the need for continued investment in R&D and manufacturing. The company also faces competition from established medical device manufacturers and potential technological obsolescence.

DexCom acknowledges that reimbursement from Medicare and private third-party healthcare payors is crucial for product success. While HCPCS codes for continuous glucose monitoring became effective on January 1, 2008, these do not guarantee reimbursement. The company is employing in-house expertise and a field-based reimbursement team to pursue coverage decisions and contracts with third-party payors. They believe demonstrating product benefits through clinical data and gaining support from advocacy groups are key to establishing reimbursement.